DPYSL2 and glioblastoma: The addition of CRMP2 phosphorylation inhibitor, (S)-lacosamide, an S-enantiomer of lacosamide, reduced cell proliferation and triggered apoptosis in all three glioblastoma cell lines examined in a concentration-dependent manner.